An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.

Abstract:

:Trastuzumab has deeply and radically changed the course of HER2-positive breast cancer disease. The recent development of a subcutaneous (SC) formulation of trastuzumab is an important step towards improved patients' care. SC trastuzumab at a fixed dose of 600 mg administered every 3 weeks for about 5 min provides a valid alternative to the IV, both in terms of efficacy and safety. This results in substantial time savings for patients, pharmacists, physicians and nursing staff, with a healthcare professionals' and patients' preference largely going to SC. In addition, the possibility to treat patients with poor venous access or to spare patients' venous capital when necessary may also be of interest.

authors

Launay-Vacher V

doi

10.1007/s00280-013-2289-4

subject

Has Abstract

pub_date

2013-12-01 00:00:00

pages

1361-7

issue

6

eissn

0344-5704

issn

1432-0843

journal_volume

72

pub_type

杂志文章
  • Effects of prochlorperazine on experimental nephrotoxicity.

    abstract::In early studies of the antitumor drug 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1nitrosourea (methyl-CCNU), animal models consistently predicted that the compound would be nephrotoxic in humans. Nephrotoxicity in cancer patients who had received methyl-CCNU was not confirmed until about 6 years after clinical trials b...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257241

    authors: Harrison SD Jr,Cox JL,Giles RC Jr

    更新日期:1982-12-01 00:00:00

  • A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

    abstract:PURPOSE:Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03908-0

    authors: Peer CJ,Schmidt KT,Kindrick JD,Eisner JR,Brown VV,Baskin-Bey E,Madan R,Figg WD

    更新日期:2019-10-01 00:00:00

  • A comparison of the quality of informed consent for phase I oncology trials over a 30-year period.

    abstract:PURPOSE:Efforts are underway in improving the informed consent process. The success of these efforts to improve quality of informed consent forms (ICFs) for phase I oncology trials has not been previously measured. METHODS:We reviewed and compared ICFs of all phase I trials for metastatic cancer conducted between 1986...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3673-x

    authors: Malik L,Cooper J

    更新日期:2018-11-01 00:00:00

  • Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.

    abstract::The aim of the present investigation was to evaluate the potential cardioprotective effect of reduced glutathione (GSH) against the delayed cardiomyopathy induced by doxorubicin (DXR) in a well-documented rat model. DXR was administered i.v. at a weekly dose of 3 mg/kg for a total of 4 doses; 250 or 500 mg/kg of GSH w...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685691

    authors: Villani F,Galimberti M,Zunino F,Monti E,Rozza A,Lanza E,Favalli L,Poggi P

    更新日期:1991-01-01 00:00:00

  • Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer.

    abstract::Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor model. The activity of lanreotide may be due to a reduction in the levels of growth factors such as insulin grow...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00685857

    authors: Maulard C,Richaud P,Droz JP,Jessueld D,Dufour-Esquerré F,Housset M

    更新日期:1995-01-01 00:00:00

  • Beta-2-microglobulin excretion: an indicator of long term nephrotoxicity during cis-platinum treatment?

    abstract::To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258126

    authors: Sørensen PG,Nissen MH,Groth S,Rørth M

    更新日期:1985-01-01 00:00:00

  • Structural development of synthetic retinoids and thalidomide-related molecules.

    abstract::The full-scale commercial appearance of antibiotics in the 1950s caused a shift in the nature of lethal diseases from infectious and acute to noninfectious and chronic. In this situation, biological response modifiers (BRMs), which are not based on selective toxicity, could be expected to be useful. Several types of B...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-003-0590-3

    authors: Hashimoto Y

    更新日期:2003-07-01 00:00:00

  • Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.

    abstract:PURPOSE:To investigate the activity and tolerance of pegylated liposomal doxorubicin in combination with vinorelbine in pretreated patients with metastatic breast cancer. PATIENTS AND TREATMENT:Thirty-six women with metastatic breast cancer were enrolled. The median age was 64 years, 80% of the patients had a performa...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-006-0236-3

    authors: Ardavanis A,Mavroudis D,Kalbakis K,Malamos N,Syrigos K,Vamvakas L,Kotsakis A,Kentepozidis N,Kouroussis C,Agelaki S,Georgoulias V,Breast Cancer Committee of the Hellenic Oncology Research Group.

    更新日期:2006-12-01 00:00:00

  • The antitumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice.

    abstract::The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258113

    authors: Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

    更新日期:1985-01-01 00:00:00

  • Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry.

    abstract:PURPOSE:Tamoxifen is a key therapeutic option for breast cancer treatment. Understanding its complex metabolism and pharmacokinetics is important for dose optimization. We examined the possibility of utilizing archival formalin-fixed paraffin-embedded (FFPE) tissue as an alternative sample source for quantification sin...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-013-2346-z

    authors: Ng ES,Kangarloo SB,Konno M,Paterson A,Magliocco AM

    更新日期:2014-03-01 00:00:00

  • Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

    abstract:PURPOSE:Thalidomide, originally developed as a sedative, was subsequently identified to have antiangiogenic properties. Lenalidomide is an antiangiogenic and immunomodulatory agent that has been utilized in the treatment of patients with brain tumors. We studied the pharmacokinetics and cerebrospinal fluid (CSF) penetr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1781-y

    authors: Muscal JA,Sun Y,Nuchtern JG,Dauser RC,McGuffey LH,Gibson BW,Berg SL

    更新日期:2012-04-01 00:00:00

  • Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

    abstract:PURPOSE:To evaluate safety and tolerability of cediranib, a highly potent and selective vascular endothelial growth factor signaling inhibitor, in Japanese patients with advanced solid tumors refractory to standard therapies. METHODS:In part A (n = 16), patients received once-daily oral cediranib (10-45 mg) to identif...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-009-0979-8

    authors: Yamamoto N,Tamura T,Yamamoto N,Yamada K,Yamada Y,Nokihara H,Fujiwara Y,Takahashi T,Murakami H,Boku N,Yamazaki K,Puchalski TA,Shin E

    更新日期:2009-11-01 00:00:00

  • Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.

    abstract:PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050023

    authors: Narita Y,Asai A,Kuchino Y,Kirino T

    更新日期:2000-01-01 00:00:00

  • Potential limitations of in vitro clonogenic drug sensitivity assays.

    abstract::P388 murine leukemic cells lines which were resistant (P388R) or sensitive (P388S) to adriamycin (adr) were used to evaluate the potential utility of in vitro clonogenic assays for detecting and quantitating the number of adr-resistant cells present in a cell mixture. The progeny of P388S cells that had been exposed f...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00269030

    authors: Dong GW,Preisler HD,Priore R

    更新日期:1984-01-01 00:00:00

  • Adriamycin-lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma.

    abstract::Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00451648

    authors: Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

    更新日期:1989-01-01 00:00:00

  • Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

    abstract::When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00695987

    authors: Kobayashi H,Takemura Y,Ohnuma T

    更新日期:1992-01-01 00:00:00

  • A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.

    abstract:PURPOSE:To confirm the efficacy and toxicity of gemcitabine and S-1 combination chemotherapy when used as a first-line therapy in patients with unresectable pancreatic cancer. METHODS:Patients with locally advanced or metastatic or recurrent pancreatic adenocarcinoma, which was histologically or cytologically proven, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-009-1059-9

    authors: Oh DY,Cha Y,Choi IS,Yoon SY,Choi IK,Kim JH,Oh SC,Kim CD,Kim JS,Bang YJ,Kim YH

    更新日期:2010-02-01 00:00:00

  • Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.

    abstract:PURPOSE:S-1 has systemic activity for locally advanced pancreatic cancer (LAPC). Here, the efficacy and safety of induction gemcitabine (GEM) and S-1 (GS) followed by chemoradiotherapy (CRT) and systemic chemotherapy using S-1 for LAPC were assessed. METHODS:The treatment consisted of four cycles of induction GS (S-1 ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3350-5

    authors: Sudo K,Hara R,Nakamura K,Kita E,Tsujimoto A,Yamaguchi T

    更新日期:2017-07-01 00:00:00

  • Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

    abstract:BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0463-1

    authors: Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

    更新日期:2002-08-01 00:00:00

  • Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

    abstract::All-trans-retinoic acid (ATRA) has been incorporated in front-line therapy for newly diagnosed acute promyelocytic leukemia (APL). We conducted a multicenter study of differentiation therapy with ATRA alone or in combination with chemotherapy followed by intensive postremission chemotherapy in patients with APL (the J...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s002800100308

    authors: Asou N,Adachi K,Tamura U,Kanamaru A,Kageyama S,Hiraoka A,Omoto E,Akiyama H,Tsubaki K,Saito K,Kuriyama K,Oh H,Kitano K,Miyawaki S,Takeyama U,Yamada O,Nishikawa K,Takahashi M,Matsuda S,Ohtake H,Ohno R

    更新日期:2001-08-01 00:00:00

  • Minimization of inflammation in the treatment of bladder tumors by intravesical instillation of adriamycin.

    abstract::The purpose of this trial was to minimize local inflammation caused by intravesical instillation of antitumor agents, especially Adriamycin, in the treatment of bladder tumor. Tranexamic acid was chosen as the solvent vehicle for Adriamycin and IV bolus injection of an antiallergic drug, Stronger neo-minophagen C, was...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00256726

    authors: Ohi Y,Okamoto K,Kawabata T,Hanafusa A,Fai CY,Kakinoki T,Kawahara M,Asechi S,Sakamoto N,Nagata S

    更新日期:1983-01-01 00:00:00

  • Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.

    abstract:PURPOSE:Inhibition of the mammalian target of rapamycin (mTOR), a regulator of hypoxia inducible factor (HIF), is an established therapy for advanced renal cell cancer (RCC). Inhibition of mTOR results in compensatory AKT activation, a likely resistance mechanism. We evaluated whether addition of the Akt inhibitor peri...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1684-y

    authors: Holland WS,Tepper CG,Pietri JE,Chinn DC,Gandara DR,Mack PC,Lara PN Jr

    更新日期:2012-01-01 00:00:00

  • A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.

    abstract:PURPOSE:MN-029 (denibulin HCl) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells. This study determined the safety, pharmacokinetics, and acute anti-vascular effects of MN-029. METHODS:Patients were treate...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1565-4

    authors: Ricart AD,Ashton EA,Cooney MM,Sarantopoulos J,Brell JM,Feldman MA,Ruby KE,Matsuda K,Munsey MS,Medina G,Zambito A,Tolcher AW,Remick SC

    更新日期:2011-10-01 00:00:00

  • Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.

    abstract:PURPOSE:To evaluate the effect of renal impairment on eribulin mesylate pharmacokinetics following a single dose in adults with advanced solid tumors. METHODS:Patients were grouped by renal function: moderate impairment (creatinine clearance [CrCl] 30-50 mL/min), severe impairment (CrCl 15-29 mL/min), or normal (CrCl ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s00280-015-2878-5

    authors: Tan AR,Sarantopoulos J,Lee L,Reyderman L,He Y,Olivo M,Goel S

    更新日期:2015-11-01 00:00:00

  • In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells.

    abstract::Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. This drug has been reported to display antitumor effects, but its use has been limited by its extreme toxicity. However, its incorporation into lipid vesicles (liposomes) has resulted in a reduction in toxic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00267946

    authors: Daoud SS,Juliano RL

    更新日期:1989-01-01 00:00:00

  • Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.

    abstract:PURPOSE:The present study was designed to determine pharmacological and biochemical properties of 2-methoxyantimycin A analogs (OMe-A1, OMe-A2, OMe-A3, and OMe-A5), which are novel antitumor compounds, and provide a basis for future pharmaceutical development, preclinical evaluation, and clinical trials. METHODS:A hig...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0978-8

    authors: Wang H,Li M,Rhie JK,Hockenbery DM,Covey JM,Zhang R,Hill DL

    更新日期:2005-09-01 00:00:00

  • Elevation of serum lipid peroxide level associated with doxorubicin toxicity and its amelioration by [dl]-alpha-tocopheryl acetate or coenzyme Q10 in mouse (doxorubicin, toxicity, lipid peroxide, tocopherol, coenzyme Q10).

    abstract::Elevations of serum lipid peroxide levels were demonstrated in mice after an equitoxic dose of doxorubicin. When BDF1 mice were injected with doxorubicin (20 mg/kg body weight, IP), lipid peroxide levels in sera were elevated 1 day after the injection and the levels declined on subsequent days. 5-Fluorouracil (400 mg/...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254735

    authors: Yamanaka N,Kato T,Nishida K,Fujikawa T,Fukushima M,Ota K

    更新日期:1979-01-01 00:00:00

  • Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.

    abstract:BACKGROUND:Peritoneal surface malignancy resulting from local dissemination is a common manifestation of treatment failure of gastrointestinal cancers. Although the management of carcinomatosis has been improved with an aggressive surgical approach of extensive cytoreduction followed by heated intraoperative intraperit...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0238-1

    authors: Sugarbaker PH,Stuart OA

    更新日期:2007-02-01 00:00:00

  • Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.

    abstract:BACKGROUND:As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-D-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. M...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-013-2358-8

    authors: Philips KB,Kurtoglu M,Leung HJ,Liu H,Gao N,Lehrman MA,Murray TG,Lampidis TJ

    更新日期:2014-02-01 00:00:00

  • Impact of metronomic neoadjuvant chemotherapy on early tongue cancer.

    abstract:PURPOSE:A metronomic schedule of chemotherapy (resulting in a greater frequency of drug delivery) has shown efficacy in head and neck cancer. Our aim was to investigate the overall survival in tongue cancer patients with metronomic neoadjuvant chemotherapy with bleomycin compared to those with surgery alone. METHODS:I...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3141-4

    authors: Kina S,Nakasone T,Kinjo T,Maruyama T,Kawano T,Arasaki A

    更新日期:2016-10-01 00:00:00